细胞外小泡
串扰
微泡
细胞内
胞外囊泡
液体活检
生物发生
生物标志物
细胞
细胞外
电池类型
生物信息学
计算生物学
诊断生物标志物
细胞生物学
生物
细胞信号
医学
代谢组学
临床试验
信号转导
转录组
微泡
病态的
蛋白质组
癌症研究
外体
蛋白质组学
精密医学
神经科学
心肌细胞
从长凳到床边
翻译(生物学)
化学
细胞生理学
病理
模式
个性化医疗
生物标志物发现
作者
Michail Spanos,Priyanka Gokulnath,Gaurav Behera,Christopher Azzam,Saumya Das
出处
期刊:Circulation Research
[Lippincott Williams & Wilkins]
日期:2026-08-13
卷期号:139 (5): e327198-e327198
标识
DOI:10.1161/circresaha.126.327198
摘要
Cardiovascular diseases remain the leading global cause of mortality, highlighting the need for improved early detection and targeted interventions. Extracellular vesicles (EVs) are nano-sized, bilipid-layered particles released by all cell types that carry RNAs, proteins, lipids, and metabolites reflective of their parent cells. They mediate intercellular communication by transferring cargo that alters recipient cell transcriptomic and proteomic states, and this property may be leveraged for therapeutic delivery. This review provides a comprehensive, cardiovascular disease-focused synthesis of EV biology with emphasis on what is clinically actionable and mechanistically novel. The review describes EV biogenesis and their multiomic cargo composition, followed by tissue-resolved and cell type-resolved EV signaling across cell types relevant to cardiovascular disease. A dedicated section addresses EV-mediated interorgan crosstalk across the heart-kidney, heart-liver, brain-heart, and adipose-heart axes as a systems-level framework for cardiometabolic disease. We next turn to translational applications, describing EV cargo composition under pathological conditions with implications for disease-related signaling and the potential for biomarker development. For liquid biopsy applications, the review introduces a 3-tier evidence framework classifying circulating EV biomarkers by clinical validation status, supported by a practical preanalytical checklist for cardiovascular plasma studies. Engineered, stem cell-derived, and RNA-loaded EV therapeutic modalities are evaluated, and active clinical trials are catalogued along with key challenges in cargo loading, biodistribution, immunogenicity, and regulatory standardization. We conclude with a structured future directions and perspectives section identifying the most tractable open questions required to advance EVs from discovery to cardiovascular clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI